Malaria No More and Novartis launch Power of One, a global digital fundraising campaign to help eliminate malaria deaths

NovartisNovartis and Malaria No More announced today the debut of the Power of One campaign, encouraging people around the world to help end child deaths from malaria. Novartis will support the campaign financially and donate up to three million Coartem® Dispersible treatments to match antimalarials funded by the public. The company's commitment to Power of One aligns with its long history in the fight against malaria; the Novartis Malaria Initiative is one of the largest access-to-medicine programs in the healthcare industry.

Malaria is a preventable and treatable disease, but it still kills a child every minute. It is estimated that over 300 million additional treatments will be needed to treat malaria patients across Africa between now and the end of 2015. The Power of One campaign aims to address this treatment gap through direct donations and existing government commitments. Every dollar donated to the campaign will buy and deliver a treatment to a child diagnosed with malaria.

"I am proud of the significant and longstanding commitment Novartis has to the fight against malaria. For all our progress though, there's still more work to do" said Joseph Jimenez, CEO of Novartis. "We need more help to close the treatment gap and Power of One offers everyone a chance to engage and make a difference for children suffering from malaria."

Harnessing social, mobile, and e-commerce technologies, Power of One enables the public to purchase a treatment and track the journey of a treatment. Donors will be able to see the effect of their donation on the ground, share information with their networks and recruit other donors.

"It's unacceptable that a child dies every minute for lack of a dollar's worth of treatment," said Martin Edlund, CEO, Malaria No More. "We're urging the world to join the Power of One campaign and to donate and engage their friends in this fight."

Novartis is the exclusive treatment sponsor of the Power of One campaign, joining some of the world's most innovative companies. Additional sponsors include Alere Inc., which will provide malaria rapid diagnostic tests, 21st Century Fox, AHAlife.com, Causes.com, Time Warner, Twitter, Venmo and others. Zambia will be the first country to receive deliveries of treatments and tests as a result of the Power of One campaign.

Novartis reaches 200 million deliveries of Coartem® Dispersible
Since 2009, Novartis has delivered 200 million treatments of its pediatric antimalarial Coartem® Dispersible without profit to more than 50 malaria-endemic countries. Never before have so many pediatric treatments been distributed in such a short time frame for children suffering from malaria. The 200 millionth treatment was delivered to Zambia, which also received the first consignment of Novartis treatments for the Power of One campaign, raised during World Malaria Day on April 25, 2013.

"MMV applauds Novartis on this laudable achievement," said David Reddy, CEO of Medicines for Malaria Venture. "Novartis has done a tremendous job of bringing an innovative drug to the vulnerable young victims of malaria in Zambia and over 50 other countries, giving it global reach. We at MMV are proud to have partnered with Novartis on the development of this important formulation."

The Novartis Malaria Initiative is one of the largest access-to-medicine programs in the healthcare industry. Moving forward, Novartis is committed to malaria elimination by driving the development of the next generation antimalarials, with two new classes of anti-malaria drugs currently in development. The most advanced compound is in Phase II clinical trials.

About Novartis
Novartis provides innovative healthcare solutions that address the evolving needs of patients and societies. Headquartered in Basel, Switzerland, Novartis offers a diversified portfolio to best meet these needs: innovative medicines, eye care, cost-saving generic pharmaceuticals, preventive vaccines and diagnostic tools, over-the-counter and animal health products. Novartis is the only global company with leading positions in these areas. In 2012, the Group achieved net sales of USD 56.7 billion, while R&D throughout the Group amounted to approximately USD 9.3 billion (USD 9.1 billion excluding impairment and amortization charges). Novartis Group companies employ approximately 131,000 full-time-equivalent associates and operate in more than 140 countries around the world.

Most Popular Now

Most popular vitamin and mineral supplements provi…

The most commonly consumed vitamin and mineral supplements provide no consistent health benefit or harm, suggests a new study led by researchers at St. Michael's Hospital...

AstraZeneca heads to 2018 ASCO Annual Meeting with…

AstraZeneca and MedImmune, its global biologics research and development arm, head to the 2018 American Society of Clinical Oncology (ASCO) Annual Meeting in Chicago, US...

Tiny particles could help fight brain cancer

Glioblastoma multiforme, a type of brain tumor, is one of the most difficult-to-treat cancers. Only a handful of drugs are approved to treat glioblastoma, and the median ...

New approach to immunotherapy leads to complete re…

A novel approach to immunotherapy developed by researchers at the National Cancer Institute (NCI) has led to the complete regression of breast cancer in a patient who was...

Spiolto® Respimat® enables greater physical activi…

Boehringer Ingelheim announced data which add to the growing body of evidence that show Spiolto® (tiotropium/olodaterol) Respimat® enables greater physical activity in pa...

Amgen Foundation and Harvard team up to offer free…

The Amgen Foundation and Harvard University today announced plans to launch a free online science education platform uniquely designed to level the playing field for aspi...

The Pfizer Foundation announces $5 million in gran…

The Pfizer Foundation announced a new $5 million grant commitment to initiatives in low- and middle-income countries that provide family planning access and education for...

Study finds antioxidant-enriched vitamin reduces r…

Researchers at Children's Hospital Colorado (Children's Colorado) and the University of Colorado School of Medicine have found that taking a specially formulated antioxid...

New drugs could also be deployed against lung and …

A new anti-cancer drug may be effective against a wider range of cancers than previously thought. Using a mouse model and samples taken from cancer patients, a team from ...

What would help or hinder patient participation in…

As clinical trials gear up with the aim of attaining the first FDA-approved treatments for mitochondrial disease, a new study reports for the first time what patients and...

Pfizer to expand venture investing with $600 milli…

Pfizer Inc. (NYSE:PFE) today announced it plans to invest $600 million in biotechnology and other emerging growth companies through Pfizer Ventures, the company’s venture...

Update on Phase III clinical trials of lanabecesta…

AstraZeneca and Eli Lilly and Company (Lilly) are discontinuing the global Phase III clinical trials of lanabecestat, an oral beta secretase cleaving enzyme (BACE) inhibi...